Arena has four other drugs in its research and development pipeline: one for arterial thrombosis, one for pulmonary hypertension, a Niacin receptor for arteriosclerosis and a treatment for Type II diabetes. On two of these drugs, Arena is collaborating with industry giant Merck and Ortho-McNeil-Janssen.
No offense, but that must be some old info you are looking at. Those partnerships have expired. They do have a promising pipeline that is more broad ranging than it was back then in 2010 and their patented IP has also expanded to include a suite of compounds with identified therapeutic potential.
I do not know where you investors get your information to buy stock, but I knew about ARNA's pipeline prior to my buys. The information is common knowledge and I never rely on articles released by SA, The Street, The Fool, or any other BS rag. I do all my research with the company prior to buying any stock. I averaged in at $2.25 per share. I have a cash account with all ARNA shares and a GTC+EXT set at $80.00 per share.
Stockranker? Another guy says the information is old? Is that true? If you do do your due dilegence you are the one to ask because the comany never said anything abouth these 2 partnerships and it just came out today???